Drug safety
The first approved myostatin blocker is here. What it actually means for muscle growth
By Kareem Brown
Published · Updated

On September 11, 2026, the FDA approved Isembyld (apitegromab-mstn), the first spinal muscular atrophy treatment that targets muscle directly rather than the genetic defect behind the disease.
Existing SMA drugs work on the SMN2 gene to slow nerve loss. Isembyld takes a different route: it blocks myostatin, a protein that limits muscle growth, aiming to preserve the muscle patients still have.
That makes it an add-on, not a replacement. The approval is for adults and children aged two and older who are already on an SMN2-targeted treatment such as nusinersen or risdiplam.
Why biohackers care about myostatin
Myostatin is the body's brake on muscle growth. Mice and cattle born without a working myostatin gene grow dramatically more muscle, and the rare humans with myostatin mutations are visibly muscular from infancy.
Apitegromab blocks myostatin before it switches on, by binding its inactive precursor forms. That precision matters: earlier drugs hit the wider activin receptor pathway and picked up off-target effects.
The trial behind the approval
The phase 3 SAPPHIRE trial, published in The Lancet Neurology, enrolled 188 people with nonambulatory type 2 or type 3 SMA, aged 2 to 21, across 48 hospitals in Europe and the US. Everyone stayed on their existing SMN2-targeted therapy.
In the primary analysis of children aged 2 to 12, motor function scores improved slightly on apitegromab while declining on placebo - a difference of 1.8 points on the HFMSE scale over 52 weeks.
The recommended 10 mg/kg dose performed best, with a 2.2-point advantage over placebo. A higher 20 mg/kg dose added nothing, which is why the label recommends only the lower dose.
About 30 percent of treated patients gained more than 3 points of motor function, versus 12.5 percent on placebo. On a progressive disease, holding or gaining function is the outcome that matters.
Does it grow muscle in healthy people?
No trial has tested apitegromab for muscle growth in healthy adults. The closest data is EMBRAZE, published in Nature Medicine: adults with obesity losing weight on tirzepatide kept 54.9 percent more lean mass with apitegromab over 24 weeks. That is muscle preservation during weight loss, not new growth.
Earlier myostatin blockers sketch the same pattern. Bimagrumab added lean mass in older adults with type 2 diabetes. ACE-031 raised muscle mass in healthy volunteers, but development stopped after bleeding and blood-vessel side effects.
Mass and function are also different endpoints. In inclusion body myositis, bimagrumab increased muscle volume without improving walking ability. Bigger muscle on a scan has not reliably meant stronger muscle in the gym.
The safety picture
The label carries cautions around bone health: treatment has been linked to fractures, and patients with low bone density or a fracture history should discuss that with their doctor.
It is not known whether the drug harms an unborn baby or passes into breast milk. Scholar Rock says the safety profile was consistent with its earlier trials, which have now run for more than four years.
How to get it legally in the US
There is exactly one legal route: a prescription from a specialist, usually through an SMA or neuromuscular care center. It is not a pill or a home injection.
Isembyld is given as an intravenous infusion once every four weeks, taking one to two hours, administered by a healthcare professional at an infusion center, hospital, or through home infusion services.
Scholar Rock told Reuters the net annual price would be about $310,000 for a typical patient in the 35 to 45 kg range. What a family actually pays out of pocket depends on their insurance; the company's Scholar Rock Supports program handles insurance navigation and financial assistance for eligible patients.
Outside the United States
The FDA approval covers the United States only. In Europe, Scholar Rock resubmitted its EMA application on October 8, 2026 after withdrawing an earlier one; the agency has not decided. In the UK, the company told Muscular Dystrophy UK it will not seek approval for now, but still hopes to bring the drug there in future.
What is not a route: grey-market sellers offering apitegromab or similar myostatin blockers online. Those products are unapproved and unregulated - and a fragile biologic that needs cold-chain handling and IV dosing cannot be safely self-sourced.
What this means for you
If you or your child has SMA and is already on an SMN2-targeted drug, this approval is a genuine new option to raise with your neuromuscular specialist.
If you are a healthy lifter, watch the pathway rather than this product. Isembyld is a weight-dosed IV biologic priced for a rare disease, with zero evidence of added muscle in healthy people. The real signal to track is whether selective myostatin blockade ever shows growth plus function in healthy-adult trials.
Open questions remain: the trial covered nonambulatory type 2 and 3 SMA, so benefit in ambulatory or treatment-naive patients is unproven, and adults were approved on the strength of the broader dataset. This article is information, not medical advice.
Sources (10)
- FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy (U.S. Food and Drug Administration)
- Isembyld (apitegromab-mstn) Prescribing Information (FDA label, BLA 761463)
- SAPPHIRE phase 3 trial of apitegromab in nonambulatory type 2 or type 3 SMA (ClinicalTrials.gov, NCT05156320; published in The Lancet Neurology, 2025)
- Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn) (company press release, September 11, 2026)
- Scholar Rock says its first muscle-targeted SMA therapy will cost about $310,000 annually (Reuters, September 14, 2026)
- Scholar Rock Resubmits Apitegromab Marketing Authorisation Application to EMA
- Muscular Dystrophy UK: apitegromab will not be submitted for approval in the UK
- Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results
- Apitegromab with tirzepatide in obesity (EMBRAZE), Nature Medicine
- SAPPHIRE phase 3 trial, The Lancet Neurology
This is news reporting and not medical advice.